Respivant RVT1601-CC-04 SCENIC: Randomized double blind placebo controlled dose ranging efficacy and safety study with inhaled RVT-1601 for the treatment of persistent cough in patients with IPF
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Respivant Sciences, GmbH
Start Date
October 21, 2019
End Date
October 14, 2020
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Respivant Sciences, GmbH
Start Date
October 21, 2019
End Date
October 14, 2020